These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 28887583

  • 1. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P, Liu L, Yin Y, Zhao Z, Zhang Y, Amponsah PS, Xiao X, Bauer N, Abukiwan A, Nwaeburu CC, Gladkich J, Gao C, Schemmer P, Gross W, Herr I.
    Cancer Lett; 2016 Apr 01; 373(1):130-137. PubMed ID: 26828016
    [Abstract] [Full Text] [Related]

  • 3. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ, Wang WX, Lin L, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2010 Jan 01; 32(1):17-21. PubMed ID: 20211060
    [Abstract] [Full Text] [Related]

  • 4. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.
    Int J Cancer; 2007 Mar 15; 120(6):1355-63. PubMed ID: 17131328
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.
    Cancer Lett; 2017 Aug 28; 402():1-8. PubMed ID: 28536008
    [Abstract] [Full Text] [Related]

  • 6. Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone.
    Prashanth N, Meghana P, Sandeep Kumar Jain R, Pooja S Rajaput, Satyanarayan N D, Raja Naika H, Kumaraswamy H M.
    Sci Total Environ; 2024 Mar 01; 914():169727. PubMed ID: 38163613
    [Abstract] [Full Text] [Related]

  • 7. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA.
    Cancer Res; 2004 Jun 01; 64(11):3761-6. PubMed ID: 15172981
    [Abstract] [Full Text] [Related]

  • 8. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.
    Clin Cancer Res; 2015 Dec 15; 21(24):5563-77. PubMed ID: 26228206
    [Abstract] [Full Text] [Related]

  • 9. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J, Yang J, Ramachandran V, Arumugam T, Deng D, Li Z, Xu L, Logsdon CD.
    PLoS One; 2015 Dec 15; 10(12):e0144969. PubMed ID: 26709920
    [Abstract] [Full Text] [Related]

  • 10. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC.
    Pharmacogenet Genomics; 2006 Jun 15; 16(6):429-38. PubMed ID: 16708051
    [Abstract] [Full Text] [Related]

  • 11. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
    Bjånes TK, Jordheim LP, Schjøtt J, Kamceva T, Cros-Perrial E, Langer A, Ruiz de Garibay G, Kotopoulis S, McCormack E, Riedel B.
    Drug Metab Dispos; 2020 Mar 15; 48(3):153-158. PubMed ID: 31871136
    [Abstract] [Full Text] [Related]

  • 12. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H.
    Eur J Cancer; 2015 Nov 15; 51(16):2480-9. PubMed ID: 26254808
    [Abstract] [Full Text] [Related]

  • 13. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug 15; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 14. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
    Dong J, Zhao YP, Zhou L, Zhang TP, Chen G.
    Arch Med Res; 2011 Jan 15; 42(1):8-14. PubMed ID: 21376256
    [Abstract] [Full Text] [Related]

  • 15. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF, Wang L, Huang WY, Cai X, Cui JJ, Wang LW.
    Asian Pac J Cancer Prev; 2013 Jan 15; 14(12):7529-36. PubMed ID: 24460329
    [Abstract] [Full Text] [Related]

  • 16. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M, Zhang Y, Yang J, Cui X, Zhou Z, Zhan H, Ding K, Tian X, Yang Z, Fung KA, Edil BH, Postier RG, Bronze MS, Fernandez-Zapico ME, Stemmler MP, Brabletz T, Li YP, Houchen CW, Li M.
    Gastroenterology; 2020 Feb 15; 158(3):679-692.e1. PubMed ID: 31711924
    [Abstract] [Full Text] [Related]

  • 17. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):679-86. PubMed ID: 19639316
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 19. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 12; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 20. miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
    Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI.
    Cancer Lett; 2013 Jul 01; 334(2):211-20. PubMed ID: 23073476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.